account_num,net_change,tag,tag_depth,cik
3395,-70000.0,AccountsPayableAndAccruedLiabilitiesNoncurrent,3,1739426_RVL PHARMACEUTICALS PLC
2552,-15395000.0,AccruedLiabilitiesCurrent,2,1739426_RVL PHARMACEUTICALS PLC
2737,-1442000.0,LongTermDebtAndCapitalLeaseObligationsCurrent,3,1739426_RVL PHARMACEUTICALS PLC
2809,-10000.0,FinanceLeaseLiabilityCurrent,3,1739426_RVL PHARMACEUTICALS PLC
2347,-17802000.0,AccountsPayableAndAccruedLiabilitiesCurrent,3,1739426_RVL PHARMACEUTICALS PLC
2398,-2407000.0,AccountsPayableCurrent,2,1739426_RVL PHARMACEUTICALS PLC
2089,128510000.0,Assets,1,1739426_RVL PHARMACEUTICALS PLC
2091,70259000.0,AssetsNoncurrent,2,1739426_RVL PHARMACEUTICALS PLC
1827,69747000.0,IntangibleAssetsNetIncludingGoodwill,2,1739426_RVL PHARMACEUTICALS PLC
1732,13900000.0,IntangibleAssetsNetExcludingGoodwill,2,1739426_RVL PHARMACEUTICALS PLC
1711,55847000.0,Goodwill,1,1739426_RVL PHARMACEUTICALS PLC
1634,512000.0,OperatingLeaseRightOfUseAsset,2,1739426_RVL PHARMACEUTICALS PLC
868,56975000.0,AssetsCurrent,2,1739426_RVL PHARMACEUTICALS PLC
260,784000.0,InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings,4,1739426_RVL PHARMACEUTICALS PLC
455,784000.0,InventoryNet,2,1739426_RVL PHARMACEUTICALS PLC
2603,-49721000.0,NoninterestIncome,1,1739426_RVL PHARMACEUTICALS PLC
2877,-44000.0,AccruedIncomeTaxesCurrent,2,1739426_RVL PHARMACEUTICALS PLC
2841,-44000.0,TaxesPayableCurrent,2,1739426_RVL PHARMACEUTICALS PLC
1133,13310000.0,RestructuringSettlementAndImpairmentProvisions,3,1739426_RVL PHARMACEUTICALS PLC
1117,-4062000.0,GainLossOnSaleOfBusiness,1,1739426_RVL PHARMACEUTICALS PLC
825,13310000.0,GoodwillAndIntangibleAssetImpairment,2,1739426_RVL PHARMACEUTICALS PLC
1182,-5636000.0,GainLossOnDispositionOfIntangibleAssets,1,1739426_RVL PHARMACEUTICALS PLC
1367,1462000.0,WriteOffOfDeferredDebtIssuanceCost,1,1739426_RVL PHARMACEUTICALS PLC
2546,-2407000.0,AccountsPayableTradeCurrent,3,1739426_RVL PHARMACEUTICALS PLC
2095,297000.0,DiscontinuedOperationTaxEffectOfDiscontinuedOperation,2,1739426_RVL PHARMACEUTICALS PLC
2638,-1442000.0,DebtCurrent,2,1739426_RVL PHARMACEUTICALS PLC
830,13310000.0,ImpairmentOfIntangibleAssetsExcludingGoodwill,1,1739426_RVL PHARMACEUTICALS PLC
3426,-70000.0,AccruedIncomeTaxesNoncurrent,2,1739426_RVL PHARMACEUTICALS PLC
990,-878000.0,GainLossOnDispositionOfAssets,4,1739426_RVL PHARMACEUTICALS PLC
1369,-1462000.0,GainsLossesOnExtinguishmentOfDebt,1,1739426_RVL PHARMACEUTICALS PLC
802,13310000.0,AssetImpairmentCharges,1,1739426_RVL PHARMACEUTICALS PLC
1631,-2229000.0,ForeignCurrencyTransactionGainLossBeforeTax,2,1739426_RVL PHARMACEUTICALS PLC
1914,-13867000.0,IncomeLossFromDiscontinuedOperationsNetOfTax,3,1739426_RVL PHARMACEUTICALS PLC
2423,-13570000.0,DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax,3,1739426_RVL PHARMACEUTICALS PLC
2716,-1432000.0,LongTermDebtCurrent,2,1739426_RVL PHARMACEUTICALS PLC
3154,-19723000.0,LiabilitiesCurrent,2,1739426_RVL PHARMACEUTICALS PLC
3303,-18000.0,LongTermDebtAndCapitalLeaseObligations,2,1739426_RVL PHARMACEUTICALS PLC
1854,4572000.0,InterestAndDebtExpense,2,1739426_RVL PHARMACEUTICALS PLC
2149,-69824000.0,IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments,3,1739426_RVL PHARMACEUTICALS PLC
2257,-51712000.0,IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,2,1739426_RVL PHARMACEUTICALS PLC
1820,-51712000.0,IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest,3,1739426_RVL PHARMACEUTICALS PLC
1077,-51692000.0,ProfitLoss,2,1739426_RVL PHARMACEUTICALS PLC
1912,-51692000.0,NetIncomeLoss,1,1739426_RVL PHARMACEUTICALS PLC
1709,3110000.0,InterestExpense,1,1739426_RVL PHARMACEUTICALS PLC
2590,-51692000.0,NetIncomeLossAvailableToCommonStockholdersBasic,2,1739426_RVL PHARMACEUTICALS PLC
110,-49721000.0,RevenueFromContractWithCustomerExcludingAssessedTax,2,1739426_RVL PHARMACEUTICALS PLC
581,17276000.0,OperatingCostsAndExpenses,2,1739426_RVL PHARMACEUTICALS PLC
491,3966000.0,ResearchAndDevelopmentExpense,2,1739426_RVL PHARMACEUTICALS PLC
144,9456000.0,CostOfRevenue,1,1739426_RVL PHARMACEUTICALS PLC
171,9456000.0,CostOfGoodsAndServicesSold,2,1739426_RVL PHARMACEUTICALS PLC
3383,-61000.0,DeferredIncomeTaxLiabilitiesNet,2,1739426_RVL PHARMACEUTICALS PLC
2903,-51692000.0,NetIncomeLossAvailableToCommonStockholdersDiluted,2,1739426_RVL PHARMACEUTICALS PLC
3378,-18000.0,FinanceLeaseLiabilityNoncurrent,3,1739426_RVL PHARMACEUTICALS PLC
2130,-6262000.0,NonoperatingIncomeExpense,1,1739426_RVL PHARMACEUTICALS PLC
1112,99255000.0,OperatingExpenses,1,1739426_RVL PHARMACEUTICALS PLC
3379,-94000.0,OperatingLeaseLiabilityNoncurrent,3,1739426_RVL PHARMACEUTICALS PLC
3796,-225000.0,LiabilitiesOtherThanLongtermDebtNoncurrent,3,1739426_RVL PHARMACEUTICALS PLC
3645,-243000.0,LiabilitiesNoncurrent,2,1739426_RVL PHARMACEUTICALS PLC
3465,-77417000.0,Liabilities,1,1739426_RVL PHARMACEUTICALS PLC
3661,-992000.0,CommonStockValue,3,1739426_RVL PHARMACEUTICALS PLC
3750,-619323000.0,AdditionalPaidInCapital,1,1739426_RVL PHARMACEUTICALS PLC
3834,-569222000.0,RetainedEarningsAccumulatedDeficit,1,1739426_RVL PHARMACEUTICALS PLC
3316,-51093000.0,StockholdersEquity,1,1739426_RVL PHARMACEUTICALS PLC
3260,-51093000.0,StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest,2,1739426_RVL PHARMACEUTICALS PLC
3917,-128510000.0,LiabilitiesAndStockholdersEquity,2,1739426_RVL PHARMACEUTICALS PLC
232,-40265000.0,GrossProfit,1,1739426_RVL PHARMACEUTICALS PLC
601,81979000.0,SellingGeneralAndAdministrativeExpense,3,1739426_RVL PHARMACEUTICALS PLC
961,-878000.0,GainLossOnSaleOfPropertyPlantEquipment,1,1739426_RVL PHARMACEUTICALS PLC
1002,-10576000.0,GainLossOnDispositionOfAssets1,1,1739426_RVL PHARMACEUTICALS PLC
1264,-58990000.0,OperatingIncomeLoss,1,1739426_RVL PHARMACEUTICALS PLC
3809,-1700000.0,AccumulatedOtherComprehensiveIncomeLossNetOfTax,2,1739426_RVL PHARMACEUTICALS PLC
